Abstract
Treatment failures following putatively curative resections for circumscribed neoplasms are well recognized and the recurrence patterns have been analyzed. These observations compel us to reshape our conceptual model, for such cancers, from one of malignancy as a localized process to that of a regionalized process. Consequently, treatments should evolve to include not only the primary cancer (removedby surgery) but also the entire anatomic region (peritoneal cavity). Regionalized processes command a combined-modality approach to effect cure or, at least, to favorably alter the natural history of the disease. It follows, then, that if for a given neoplasm the available agents are not ideal and, furthermore, that no new agents have been developed in the recent past that offer a hope of improved survival ; we must exploit the agents at hand in the most effective manner.
Chapter PDF
References
Clarkson B, O’Connor A, Wilson L et al. (1964) The physiologic disposition of 5-fluo-rouracil and 5-fluoro-2(l)-deoxyuridine in man. Clin Pharmacol Ther 5: 581–610
Chabner BA, Young RC (1973) Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52: 1804–1811
Myers CE, Collins JM (1983) Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1 (5): 395–407
Dedrick RL, Myers CE, Bungay PM, DeVita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62: 1–11
Flessner MF, Dedrick RL, Schulte JS (1984) A distributed model of periotoneal plasma transport: theoretical considerations. Am J Physiol 246: R597–R607
Flessner MF, Fenstermacher JD, Blasberg RG, Dedrick RL (1985) Peritoneal absorption of macromolecules studied by quantitative autogradiography. Am J Physiol 248: H26–H32
Flessner MF, Fenstermacher JD, Blasberg RG (1985) A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol 248: F425–F435
Flessner MF, Dedrick RL, Schulte JS (1985) A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. Am J Physiol 248: F413–F424
Flessner MF, Dedrick RL, Schltz JS (1985) Exchange of macromolecules between peritoneal cavity and plasma. Am J Physiol: H15–H25
Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12(3): 1–6
Speyer JL, Sugarbaker PH, Collin JM, Dedrick RL, Kleeker RW, Meyers CE (1981) Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41: pp 1916–1922
Sugarbaker PH, Gianola FJ, Speyer JL, Wesley R, Barofsky I, Meyers CE (1985) Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with a primary colon or rectal cancer. Semin Oncol 12(3): 101–111
Dedrick RL, Flessner MF, Collins JM et al. (1982) Is the peritoneum a membrane? ASAIO 5(1): 1–8
Dunnick NR, Jones RB, Doppman JL, Speyer J, Myers CE (1979) Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR 133: 221–223
Feldman GB, Knapp RI (1974) Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol. 119: 991–994
Leichner PT, Rosenshein NB, Leibel SA et al. (1980) Distribution and tissue dose of in-traperitoneally administered radioactive chromic phosphate in New Zealand white rabbits. Radiology 134: 729–734
Rosenshein N, Blake D, McIntyre P et al. (1978) The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol 6: 106–110
Teckhoff H, Schecter H (1968) A bacteriologically safe peritoneal access device. ASAO 12:181
Tenckhoff H (1974) Manual for chronic peritoneal dialysis. University of Washington School of Medicine, Seattle
Twardowski ZJ (1985) Intraperitoneal therapy in renal failure. Semin Oncol 12(3): 81–89
Piccart M J, Speyer JL, Markman M, ten Bokkel-Huinink WW, Alberts D, Jenkins J, Muggia F (1985) Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol 12(3): 90–96
Jenkins J, Sugarbaker PH, Gianola FJ, Myers CE (1982) Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter. Surg Gynecol Obstet 154: 858–864
Jenkins J (1983) Managing intraperitoneal chemotherapy: a medical, nursing and personal challenge. Semin Oncol 12(3): 97–100
Davis AS, Reed WP (1983) A leak-free technique for open insertion of peritoneal dialysis catheters. Surg Gynecol Obstet 157: 579–580
Cerilli J, Walker J, Bay W (1983) A new technique for placement of catheters for peritoneal dialysis. Sur Gynecol Obstet 156: 663–664
Ozols RF, Myers CE, Young RC (1984) Intraperitoneal chemotherapy. Ann Intern Med 100: 1 118–120
Longo DL, Young RC (1981) The natural history and treatment of ovarian cancer. Annu Rev Med 32: 475–490
Buchsbaum HJ, Lifshitz S (1984) Staging and surgical evaluation of ovarian cancer. Semin Oncol 11(3): 227–237
Kavanagh JJ (1985) Investigational therapies for epithelial ovarian cancer. Clin Obstet Gynec 28(4): 846–852
Young RC (1984) Ovarian cancer treatment: progress of paralysis? Semin Oncol 11(3): 327–329
Ozols RF, Young RC (1984) Chemotherapy of ovarian cancer. Semin Oncol 11(3): 251–263
Thigpen JT, Vance RB, Lodovico B, Khansur TF (1984) New drugs and experimental approaches in ovarian cancer treatment. Semin Oncol 11(3): 314–326
Hamilton TC, Young RC, Ozols RF (1984) Experimental model systems of ovarian cancer: applications to the design and evaluation of new teatment approaches. Semin Oncol 11(3): 285–298
Ozols R (1985) Intraperitoneal chemotherapy in the management of ovarian cancer. Semin Oncol 12(3): 75–80
Cohen CJ (1985) Surgical considerations in ovarian cancer. Semin Oncol 12(3): 53–56
Thigpen T, Blessing JA (1985) Current therapy of ovarian carcinoma: an overview. Semin Oncol 12(3): 47–52
Alberts DS, Young L, Mason N, Salmon SE (1985) In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 12(3): 38
Tong D, Russell AH, Dawson Le et al. (1983) Second laparotomy for proximal colon cancer. Am J Surg 145: 382–386
Speyer JL (1985) The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 12(3): 23–28
Douglass HO (1985) Gastric cancer: overview of current therapies. Semin Oncol 12(3): 57–62
Wilson RE (1985) Surgical considerations in gastric cancer. Semin Oncol 12(3): 63–68
Brenner DE (1986) Intraperitoneal chemotherapy: a review. J Clin Oncol 4(7): 1135–1147
Higgins GA Jr, Lyndon EL, Dwight RW, Keeher RJ (1978) The case of adjuvant 5-fluo-rouracil in colorectal cancer. Cancer Clin Trials, Spring: 35–41
Christophidis N, Vajda FJE, Lucas I, Drummer O, Moon WJ, Lornis WJ (1978) Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokin 3: 33–336
deBruijn EA, VanOosterom AT, Tjaden UR, Recuwijk HJEM, Pinedo HM (1985) Pharmacology of 5-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Res 45: 5931–5935
Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, DeVita VT, Myers CE (1980) Phase-I and pharmacological studies of 5-fluorouracil administration intraperitoneally. Cancer Res 40: 567–572
Jones RB, Collins JM, Myers CE, Brooks AE, Hubbard SM, Balow JE, Brennan MF, Dedrick RL, DeVita VT (1981) High-volume intraperitoneal chemotherapy with method-trexate in patients with cancer. Cancer Res 41: 55–59
Howel SB, Chu BB, Wung WE et al. (1981) Long-duration intracavitary infusion of methotrexate with systemic Leucovorin protection in patients with malignant effusions. J Clin Invest 67: 1161–1170
Howell SB (1985) Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents. Semin Oncol 12(3): 17–22
Ozols RF, Young RC (1985) High-dose cisplatin therapy in ovarian cancer. Semin Oncol 12(4): 21–30
Lopez JA, KrisKorian JG, Reich SD, Smyth RD, Lee FH, Isseil BF (1985) Clinical pharmacology of intraperitoneal cisplatin. Gynecol ncol 20: 1–9
Makman M, Cleary S, Howells SB (1985) Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. Eur J Cancer Clin Oncol 21 (9): 1015–1018
Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitoneal cis-diamminedich-loroplatinum with system thiosulfate protection. Cancer Res 43: 1426–1431
ten Bokkel-Huinink WW, Bubbelman R, Aartsen E, Franklin H, McVie JG (1985) Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol 12(3): 43–46
Pretonius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, LaGasse LD (1983) Pharmacokinetics of i.p. cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67(12): 1085–1092
Ozols RF, Young RC, Speyer JL et al. (1982) Phase-I and pharmacologic studies of adri-amycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42: 4265–4269
Howell SB, Pfeifle CE, Olshen, RA (1984) Intraperitoneal chemotherapy with melphal-an. Ann Int Med 101: 14–18
Holcenberg J, Anderson T, Ritch P et al. (1983) Intraperitoneal chemotherapy with mel-phalan plus glutaminase. Cancer Res 43: 1381–1388
King ME, Pfeifle CE, Howell SB (1984) Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J Clin Oncol 2: 662–669
Markman M, Cleary S, Lucas WE, Howell SB (1985) Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarianm carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol 3: 7
Markman M (1985) Melphalan and cytarabine administered intraperitonealy as single agents and combination intraperitoneal chemotherapy with cisplatin and cytarabine. Semin Oncol 12(3): 33–37
Weiss G, Von Hoff DD (1985) Human tumor cloning assay: clinical applications for ovarian, gastric, pancreatic and colorectal cancers. Semin Oncol 12(3): 69–74
Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RB, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnern EM, Spiegel RJ, Zigheboim J (1985) Intraperitoneal recombinant a-interferon for “salvage” immunotherapy in stage-III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer Res 45: 4447–4453
Lotze MT, Custer MC, Rosenberg SA (1987) Intraperitoneal administration of interleu-kin-2 in patients with cancer. Arch Surg (in press)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Wolf, B.E., Sugarbaker, P.H. (1988). Intraperitoneal Chemotherapy and Immunotherapy. In: Schlag, P., Hohenberger, P., Metzger, U. (eds) Combined Modality Therapy of Gastrointestinal Tract Cancer. Recent Results in Cancer Research, vol 110. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83293-2_37
Download citation
DOI: https://doi.org/10.1007/978-3-642-83293-2_37
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-83295-6
Online ISBN: 978-3-642-83293-2
eBook Packages: Springer Book Archive